cncpt-artikel_lb_atf
Deep PSA declines with apalutamide is associated with lower risk for worsened QoL
An additional study to the TITAN and SPARTAN Studies supports findings suggesting preserved quality of life despite changes in prostate-specific antigen in patients treated with apalutamide.